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predicted efﬁcacy of ﬁrst-line rilpivirine-containing regimens in
antiretroviral-naive Spanish patients. International Antiviral
Society-USA mutations were detected in 138 of 2781 patients
(4.9%), E138A (3.4%) being the most prevalent. Using the
Stanford Algorithm, 121 patients (4.4%) showed low-level or
intermediate resistance. No differences in the predicted efﬁcacy
of ﬁrst-line non-nucleoside reverse transcriptase inhibitor-based
regimens were observed. As rilpivirine becomes more widely
used in clinical practice, the evolution of its transmitted drug
resistance will need to be monitored. In addition, the exact role
of E138A singletons on rilpivirine activity as part of ﬁrst-line
regimens merits further evaluation.
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p://dx.doi.org/10.1016/j.cmi.2014.08.005The International Antiviral Society-USA (IAS-USA) update of
drug-resistance mutations in human immunodeﬁciency virus
type 1 (HIV-1) [1] describes 16 mutations associated with
resistance to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L,
Y181C/I/V, Y188L, H221Y, F227C and M230I/L. As most of the
studies characterizing transmitted drug resistance across
Europe and the USA have not looked for some of these
rilpivirine-resistance-associated mutations (RAMs) (e.g. muta-
tions at codons 138, 221 and 227) [2–5], little information on
the prevalence of transmitted rilpivirine RAMs is available
[6–8]. We have previously reported transmitted drug resis-
tance over different periods in Spain [9–11], but none of these
reports evaluated rilpivirine transmitted drug resistance. In
addition to transmitted drug resistance, we have also charac-
terized clinically relevant transmitted drug resistance. For ril-
pivirine, it may also be of interest to know how certain
singletons (e.g E138A) impact drug activity, especially when
rilpivirine is part of a fully active ﬁrst-line regimen. Again, it may
be of interest to use clinically relevant resistance to build a
therapeutic barrier with ﬁrst-line antiretroviral regimens con-
taining rilpivirine, and to compare it with other regimens that
are currently recommended for ﬁrst-line therapy.
In this study, we have investigated rilpivirine RAMs in 2781
patients fromCohorte de la Red de Investigación en Sida [12,13],
antiretroviral naive adults consulting for the ﬁrst time in collab-
orating HIV units from the public healthcare services, and
recruited during the period 2007–2011. To describe rilpivirine
RAMs we have used the 2013 update of the IAS-USA drug-
resistance mutation list [1]. To evaluate clinically relevant resis-
tance to rilpivirine, and to other ﬁrst-line antiretrovirals, we have
used the latest update of the Stanford HIV Database Algorithm (v
7.0 2014 Feb 27) [14]. Any category different from susceptible or
potential low-level resistance was considered clinically relevant.
Predicted efﬁcacy of ﬁrst-line regimens was evaluated through
their genotypic sensitivity score, which was built by scoring
susceptible as 1, intermediate (low-level or intermediate resis-
tance) as 0.5, and high-level resistance as 0. A fully active regimen
was considered when a genotypic sensitivity score of 3 was
present. The sample was described using proportion or median
(interquartile range) for categorical and continuous variables,
respectively; bivariate analysis was performed using chi-squared
or Kruskall–Wallis test as appropriate. Resistance mutations
scored by IAS-USA and Stanford HIV database were described
using prevalence, and the corresponding conﬁdence intervals
were calculated with an analytically derived variance estimator.
All the analyses were conducted using STATA software (V.11.1,
Stata Corporation, College Station, TX, USA).
IAS-USA rilpivirine RAMs were detected in 138 patients,
making a total prevalence of 4.9% (95% CI 4.1–5.8). E138Aious Diseases. Published by Elsevier Ltd. All rights reserved
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prevalence of 3.4% (95% CI 2.7–4.1), followed by E138K (0.4%,
95% CI 0.2–0.7), H221Y (0.4%, 95% CI 0.1–0.6), Y181C (0.3%,
95% CI 0.05–0.5), K101E (0.2%, 95% CI 0.025–0.4), Y188L
(0.2%, 95% CI 0.06 0.4), K101P (0.1%, 95% CI 0.01–0.3),
E138G (0.1%, 95% CI 0.02–0.3), Y181I (0.1%, 95% CI
0.01–0.3) and M230L (0.03%, 95% CI 0.001–0.2). These data
are consistent with the limited information presented so far: a
French survey [7] documents a 5% global prevalence for
rilpivirine-associated mutations, Italian researchers have pre-
sented data on a 6% prevalence [15], and data from the ECHO
& THRIVE studies have shown similar numbers [16,17]. As in
our study, E138A accounted for more than half of the preva-
lence of rilpivirine-associated mutations. There is evidence of
some impact on phenotypic resistance to rilpivirine of site-
directed mutants with changes at codon rt138 [18,19], and a
selection of this mutation by HLA-B*18-restricted cytotoxic T
lymphocytes [20] has been reported. E138A is now considered
to have an impact on rilpivirine resistance by the most recent
updates of international algorithms [14,21], but there is little
evidence on the potential impact of the E138A mutation alone
on clinical response to ﬁrst-line rilpivirine-containing regimens.
Although currently available information suggests that ﬁrst-line
rilpivirine-containing regimens are not indicated in the presence
of a baseline E138A singleton, in terms of cross-resistance
among non-nucleoside reverse transcriptase inhibitors and
nucleoside reverse transcriptase inhibitors (particularly 3TC-
FTC), clinical studies addressing this issue are needed.
As most of the isolates with rilpivirine RAMs carry E138A
singletons, we have studied clinically relevant transmitted drug
resistance, by means of the Stanford HIV Database Algorithm.
Fully resistant isolates were associated with Y188L (n = 5; 0.2%,
95% CI 0.06–0.4), Y181I and K101P (n = 2; 0.1%, 95% CI
0.01–0.3) as singletons, while another six patients showed the
combination of several mutations (A98G+K101E+Y181C,
K101E+Y181C+G190A, K101E+Y181C+G190S, L100I+M230L,TABLE 1. Clinically relevant resistance to rilpivirine, and other ﬁrs
period 2007–2011
ARV class ARV drug Intermediate Prevalence (
NRTIs Tenofovir 2 0.1 (0.01–0.3
Emtricitabine 8 0.3 (0.1–0.5)
Lamivudine 8 0.3 (0.1–0.5)
Abacavir 61 2.2 (1.6–2.8)
NNRTIs Efavirenz 33 1.2 (0.8–1.6)
Nevirapine 30 1.1 (0.7–1.5)
Rilpivirine 123 4.4 (3.6–5.2)
PIs Lopinavir 7 0.2 (0.05–0.5
Atazanavir 19 0.7 (0.4–1.01
Darunavir 3 0.1 (0.02–0.3
p values using rilpivirine as reference. Intermediate resistance was more frequently detected f
more frequently detected for efavirenz and nevirapine. For protease inhibitors, all compariso
was made (nd). Abbreviations: ARV, antiretroviral; NRTI, nucleoside reverse transcriptase in
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InY188F+M230L, L100I+M230L (n = 1; 0.04%, 95% CI 0.001–0.2,
respectively). Intermediate resistance was associated with sin-
gletons of E138A (n = 91; 3.3%, 95% CI 2.6–3.9), E138K (n = 12;
0.4%, 95% CI 0.2–0.7), L100V (n = 5; 0.2%, 95% CI 0.1–0.4),
E138G (n=4; 0.1%, 95%CI 0.04–0.4), Y181C (n=2; 0.1%, 95%CI
0.01–0.3), L100I (n = 2; 0.1%, 95%CI 0.01–0.3) andK101E (n = 1;
0.04%, 95% CI 0.001–0.2), while only six patients with the com-
bination of two or more mutations were scored as intermediate
(E138A+V179D (n = 2; 0.1%, 95% CI 0.01–0.3), K101E+E138A
(n = 2; 0.1%, 95% CI 0.01–0.3) and A98G+G190A plus
Y181C+H221Y+F227L (n = 1; 0.04%, 95% CI 0.001–0.2)). Clin-
ically relevant resistance to ﬁrst-line drugs approved in Spain is
shown in Table 1.
Evaluating the predicted efﬁcacy of a ﬁrst-line regimen may
be of importance for updating treatment guidelines and estab-
lishing recommendations on how resistance testing should be
performed on newly diagnosed patients. In our study,
rilpivirine-based ﬁrst-line regimens showed non-signiﬁcant dif-
ferences in clinically relevant transmitted drug resistance (188
and 189 patients (6.8%, 95% CI 5.8–7.7) showed any relevant
predicted resistance to any component of TDF+3TC/FTC+RPV
and ABC+3TC/FTC+RPV, respectively) compared with
efavirenz-based or nevirapine-based regimens (5.8–5.9% and
6.3%, respectively). On the other hand, regimens based on ﬁrst-
line protease inhibitors showed lower rates of predicted
resistance, compared with rilpivirine-based regimens (Table 2).
Evolution of transmitted drug resistance to rilpivirine will also
need to be monitored over the following years, as this drug
becomes more widely used in clinical practice.
Our study has several limitations. First, we have studied
patients included in Cohorte de la Red de Investigación en Sida,
a Spanish cohort of antiretroviral-naive adults. Although our
results need to be reproduced in other cohorts, our ﬁndings of
the prevalence of IAS-USA mutations are similar to those
recently reported in France and Italy. Second, our sequencing
data have been obtained through population sequencing and wet-line drugs, in antiretroviral naive Spanish adults through the
95% CI) Resistant Prevalence p
) 49 1.8 (1.3–2.3) nd
13 0.5 (0.2–0.7) nd
13 0.5 (0.2–0.7) nd
4 0.1 (0.04–0.4) nd
82 2.9 (2.3–3.6) <0.0001
98 3.5 (2.8–4.2) <0.0001
14 0.5 (0.2–0.8) reference
) 1 0.04 (0.001–0.2) <0.0001
) 2 0.1 (0.01–0.3) <0.0001
) 1 0.04 (0.001–0.2) <0.0001
or rilpivirine than for efavirenz and nevirapine; conversely, fully resistant isolates were
ns were signiﬁcant. As NRTIs are the backbone of ﬁrst-line regimens, no comparison
hibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 104.e1–104.e5
TABLE 2. Predicted reduction in efﬁcacy of rilpivirine-
containing, and other ﬁrst-line antiretroviral regimens, in
antiretroviral naive Spanish adults through the period
2007–2011
GSS <3a
n (%) (95% CI) p
NNRTI-based
regimens
RPV TDF FTC/3TC 188 (6.8) (5.8–7.7) reference
ABC FTC/3TC 189 (6.8) (5.8–7.7) reference
EFV TDF FTC/3TC 162 (5.8) (4.9–6.7) ns
ABC FTC/3TC 163 (5.9) (5.0–6.7) ns
NVP TDF FTC/3TC 174 (6.3) (5.3–7.2) ns
ABC FTC/3TC 175 (6.3) (5.4–7.2) ns
PI-based
regimens
LPV TDF FTC/3TC 70 (2.5) (1.9–3.1) <0.0001
ABC FTC/3TC 71 (2.5) (1.9–3.2) <0.0001
ATZ TDF FTC/3TC 78 (2.8) (2.2–3.4) <0.0001
ABC FTC/3TC 79 (2.8) (2.2–3.5) <0.0001
DRV TDF FTC/3TC 67 (2.4) (1.8–3.0) <0.0001
ABC FTC/3TC 68 (2.4) (1.8–3.0) <0.0001
Abbreviations: ARV, antiretroviral; NRTI, nucleoside reverse transcriptase
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor; TDF, tenofovir; ABC, abacavir; 3TC, lamivudine; FTC, emtricitabine;
EFV, efavirenz; NVP, nevirapine; LPV, lopinavir; DRV, darunavir; ATZ, atazanavir.
aGenotypic Sensitivity Score (GSS) was used to predict the efﬁcacy of ﬁrst-line
regimens. Any GSS <3 reﬂects some degree of resistance in at least one of the
components of the regimen.
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as E138A is a frequently detected mutation in antiretroviral-
naive patients as a singleton, the exact role of this mutation
and other singletons in this codon in the efﬁcacy of a ﬁrst-line
rilpivirine-containing regimen merits investigation. Clinical data
addressing this question are necessary.
In summary, we have described the prevalence of trans-
mitted drug resistance to rilpivirine throughout the period
2007–2011, and found no signiﬁcant difference in clinically
relevant transmitted drug resistance for both rilpivirine alone,
and ﬁrst-line regimens containing rilpivirine, compared with
efavirenz and nevirapine alone and in ﬁrst-line regimens con-
taining them. These ﬁndings will need to be monitored over the
following years, as rilpivirine becomes more widely used in
clinical practice, and as the exact impact of singletons, especially
at codon 138, on rilpivirine activity as a component of ﬁrst-line
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